Kartik Krishnan was named Chief Medical Officer of Pasithea Therapeutics Corp., effective May 1, 2026. As of November 15, 2026, Pasithea Therapeutics Corp. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 4, 2026, naming 1 appointment (Form 8-K, May 4, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Pasithea Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Pasithea Therapeutics Corp. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-04. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Pasithea Therapeutics Corp. files it.
Also on the record for Pasithea Therapeutics Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Vivo Opportunity Fund Holdings, L.P. | 9.99% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 6.14% of the class | 5%+ stakes | Source |
| July 1, 2026 | Stake report, Schedule 13G/A, by Coastlands Capital LP | 11.48% of the class | 5%+ stakes | Source |
| June 23, 2026 | Stake report, Schedule 13G, by Stonepine Capital Management, LLC | 5.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Ameriprise Financial, Inc. | 5.4% of the class | 5%+ stakes | Source |
| April 22, 2026 | Stake report, Schedule 13G, by Funicular Funds, LP | 7.4% of the class | 5%+ stakes | Source |
| April 8, 2026 | Stake report, Schedule 13G, by Opaleye Management Inc. | 9.99% of the class | 5%+ stakes | Source |
| February 27, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Ameriprise Financial, Inc. | 8.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 3.8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pasithea Therapeutics Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on Pasithea Therapeutics Corp. and the records around it.
Pasithea Therapeutics Corp. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Funicular Funds, LP also filed stake reports on 10 other companies: ABEONA THERAPEUTICS INC. (Nov 2026), AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026)
- Opaleye Management Inc. also filed stake reports on 12 other companies: Rezolute, Inc. (Nov 2026), Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
Watch Pasithea Therapeutics Corp.
Get an email when Pasithea Therapeutics Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pasithea Therapeutics Corp.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Pasithea Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pasithea Therapeutics Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-04 | In | Chief Medical Officer | 2026-05-01 | 8-K, 2026-05-04 |
Who leads Pasithea Therapeutics Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Kartik Krishnan, appointed, effective 2026-05-01 (filed 2026-05-04).
New leaders reset buying decisions — get the Full Report on Pasithea Therapeutics Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Pasithea Therapeutics Corp., with the record behind each one.
Find candidates like Chief Medical Officer at Pasithea Therapeutics Corp.Every change, in the filing's words
Appointed: Kartik Krishnan, Chief Medical Officer, effective 2026-05-01
On May 4, 2026, Pasithea Therapeutics Corp. (the "Company") announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.
- Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform and cutaneous neurofibromas.
- Dr. Krishnan, age 55, has over 20 years of experience in clinical development, pharmacovigilance, clinical operations, regulatory affairs, and R&D strategy.
- Prior to joining the Company, Dr. Krishnan served as Chief Executive Officer at OncoNano Medicines, a privately held company developing anti-cancer assets.
- Prior to that, Dr. Krishnan served as Chief Medical Officer at Arcus Biosciences, a discovery and clinical development company focusing on combination therapies in immuno-oncology.
- Earlier in his career, Dr. Krishnan held various clinical development and medical director roles of increasing responsibility at companies including Astex Pharmaceuticals, Genentech, Five Prime Therapeutics, BioMarin, and Amgen.
- While at Genentech, Dr. Krishnan was an integral part of the clinical team for cobimetinib (Cotellic ), contributing to its approval in the United States and Europe in 2015 for the treatment of BRAF V600E-mutant or BRAF V600K-mutant melanoma in combination with vemurafenib (Zelboraf ), and worked to establish development opportunities for this MEK inhibitor beyond melanoma.
Tools for this story
Each opens in a new tab, filled in for Pasithea Therapeutics Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
